Feb. 19 at 6:05 PM
$MDAI I put your feeling' to AI:
The "headache" you are experiencing is likely tied to several fundamental and tactical pressures facing the company:
Financial Instability: In its most recent quarterly reports, the company showed an increased net loss (reaching
$3.2 million in Q1 FY24 with an expected annual loss of
$12.5 million). Operating costs are rising, and there is a heavy dependence on the BARDA contract for revenue.
FDA Uncertainty: Although the company has highlighted
FDA submission progress, there are ongoing concerns regarding potential delays in clinical trials and the eventual commercialization path for its products.
Silence and Strategy: Analysts have noted that while international feedback has been positive, these gains are overshadowed by negative financial trends and a lack of clear guidance on future revenue outside of government contracts.
+4
